The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.15
Bid: 1.80
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.50 (27.778%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 2.15
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Company Secretary Change

7 Oct 2022 16:44

RNS Number : 2369C
Immupharma PLC
07 October 2022
 

07 October 2022

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Appointment of Company Secretary

 

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to confirm the appointment of Ward Williams Limited as Company Secretary to the Company. The appointment is with immediate effect.

 

 

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

 

For further information please contact:

 

ImmuPharma PLC (www.immupharma.com)

Tim McCarthy, Chief Executive Officer

Lisa Baderoon, Head of Investor Relations

+44 (0) 207 206 2650

 

+ 44 (0) 7721 413496

 

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

 

 

 

+44 (0) 203 368 3550

 

 

 

 

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

 

For additional information about ImmuPharma please visit www.immupharma.co.uk

 

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

 

About Ward Williams LimitedWard Williams is a leading provider of quality business support and personal financial services. They differentiate themselves through the range of services provided. Their client-focused services are delivered through two divisions: Chartered Accountants and HR Consultants, all working together from four locations in Weybridge, Uxbridge, Sunninghill and London. For more information go to: https://www.wardwilliams.co.uk/about-us/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
COSUPGGCUUPPGAM
Date   Source Headline
31st Jul 20137:00 amRNSFDA GRANTS IMMUPHARMA AMENDED SPA
8th Jul 20138:00 amRNSIMMUPHARMA APPOINTS WORLDWIDE KEY OPINION LEADERS
5th Jun 20137:00 amRNSHolding(s) in Company
23rd May 201312:29 pmRNSResult of AGM
21st May 20137:00 amRNS£50M Financing Facility - Darwin Strategic
22nd Apr 20137:00 amRNSPosting of Annual Report and AGM Notice
9th Apr 20137:00 amRNSPreliminary Results
28th Feb 20137:01 amRNSImmuPharma Commences Trading on Stuttgart Exchange
28th Jan 20134:03 pmRNSDirector/PDMR Shareholding - Replacement
28th Jan 20131:18 pmRNSDirector/PDMR Shareholding
28th Jan 20139:33 amRNSCNRS Confirms Lupuzor's (TM) Effectiveness
15th Nov 20127:30 amRNSLupuzor Presentation
5th Nov 20127:00 amRNSLupuzor Presentation
3rd Oct 20127:00 amRNSNotification of Major Interest in Shares
26th Sep 20127:01 amRNSFirst Cancer Patients in New Trial Begin Dosing
26th Sep 20127:00 amRNSInterim Results
20th Sep 20127:00 amRNSNotification of Interim Results
7th Sep 201211:12 amRNSRodman and Renshaw Conference
17th Aug 20129:11 amRNSNotification of Major Interest in Shares
11th Jul 20127:00 amRNSVoted Best Medical Research & Development Company
9th Jul 20127:00 amRNSNew Corporate Website
3rd Jul 20127:00 amRNSAppointment of Joint Broker
23rd May 201212:20 pmRNSAnnual General Meeting: 2012
17th Apr 20127:00 amRNSPosting of Annual Report and AGM Notice
27th Mar 20127:00 amRNSPreliminary Results
29th Feb 20127:00 amRNSAppoints Head of Investor Relations
24th Jan 201212:44 pmRNSDirector's Dealings
3rd Nov 20117:00 amRNSLupuzorT granted approval to start phase III
1st Nov 201110:23 amRNSNotification of Major Interest in Shares
1st Nov 201110:18 amRNSNotification of Major Interest in Shares
21st Oct 20117:00 amRNSImmuPharma regains Lupuzor rights
30th Sep 20117:00 amRNSINTERIM RESULTS ANNOUNCEMENT
23rd Sep 20119:34 amRNSNotification of Interim Results
12th Jul 20112:47 pmRNSNotification of Major Interest in Shares
19th May 201111:19 amRNSResult of Annual General Meeting
5th May 20117:00 amRNSIPP-204106 paper published
26th Apr 20114:38 pmRNSAnnual Report and Accounts & Notice of AGM
5th Apr 20117:00 amRNSPreliminary Results
30th Mar 20117:00 amRNSNotification of Preliminary Results
21st Feb 20117:00 amRNSUpdate on progress of Phase I/IIa Clinical Trial
19th Oct 20101:08 pmRNSUpdate on Phase IIa Clinical Trial
11th Oct 20102:30 pmRNSNotification of major interests in shares
11th Oct 20102:30 pmRNSAdditional Listing and Total Voting Rights
30th Sep 20107:00 amRNSInterim Results
28th Sep 201010:18 amRNSNotification of Interim Results
28th Jun 20107:00 amRNSPresentation at the International Congress
23rd Jun 20107:40 amRNSReplacement of Development release
23rd Jun 20107:00 amRNSCephalon initiates critical steps in development
17th Jun 201012:02 pmRNSResult of AGM
10th Jun 201010:55 amRNSAnnual Report and Accounts

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.